MaaT PHARMA
- Address
- 70 Avenue Tony Garnier
Sponsor Overview
Specializations
Gastrointestinal acute graft-versus-host disease
MaaT PHARMA focuses on gastrointestinal acute graft-versus-host disease, with research directed toward treatment-resistant inflammatory complications affecting the digestive tract after allogeneic hematopoietic cell transplantation.
- Salvage therapy for GI-aGvHD
- Ruxolitinib-refractory disease
- Intestinal immune dysregulation
Its clinical activity includes patients with severe GI-aGvHD who have limited response to prior therapies, reflecting a strong therapeutic interest in post-transplant inflammatory disease.
Allogeneic hematopoietic cell transplantation complications
The sponsor also studies complications associated with allogeneic hematopoietic cell transplantation in patients with hematologic malignancies, particularly immune-mediated outcomes that affect survival and recovery.
- Post-transplant complication prevention
- Overall survival in transplant recipients
- Hematologic malignancy support care
Research in this area links transplant medicine with management of complications that arise after cellular therapy for blood cancers.
Microbiome-based therapeutic approaches
MaaT PHARMA is active in microbiome-based medicine, including orally administered pooled fecal microbiotherapy for prevention of transplant-related complications and immune injury.
- Oral microbiotherapy
- Gut microbiome restoration
- Immune-microbiota interaction
This area connects intestinal microbial balance with control of post-transplant inflammatory syndromes.
Pediatric gastrointestinal transplantation disorders
The sponsor’s research also extends to pediatric patients with GI-aGvHD, addressing safety, tolerability, and feasibility of treatment in children and adolescents affected by severe post-transplant disease.
- Pediatric GI-aGvHD
- Adolescent transplant care
- Safety and tolerability in children
This clinical interest highlights the need for age-appropriate approaches in transplant-related gastrointestinal inflammation.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| A multi-center randomized, double blinded phase IIb trial evaluating oral pooled fecal microbiotherapy MaaT033 to prevent allogeneic hematopoietic cell transplantation complications |  Belgium France Germany Spain The Netherlands | Recruiting |
| Evaluation of MaaT013 Efficacy in Gastrointestinal Acute Graft-Versus-Host Disease Refractory to Ruxolitinib: A Phase III Multicenter Open-Label Trial |  Austria Belgium France Germany Italy Spain | Not Recruiting |
| Safety, Tolerability, and Feasibility of Rectal MaaT013 (Allogeneic Pooled Fecal Microbiota) in Ruxolitinib‑Refractory Pediatric and Adolescent Gastrointestinal Acute Graft‑Versus‑Host Disease | France Italy Spain The Netherlands | Not Yet Recruiting |
Data & Insights
This sponsor works with 2 molecules, of which 0 are not being studied by other sponsors.
This sponsor has worked with 77 sites across their trial portfolio.
Therapeutic Focus
- 1.Digestive System Diseases2 trials280 other sponsors
- 2.Hemic and Lymphatic Diseases1 trial249 other sponsors
Partnered Research Centres
77 centres- Address
- Deltalaan 1, 8800 Roeselare
- Address
- Num Voie 47 A 83, 47 Boulevard De L Hopital, 75013 Paris
- Address
- Ruddershove 10, 8000 Bruges
- Address
- Via Posillipo 226, 80123 Naples
- Address
- Via Cherasco 15, 10126 Turin
- Address
- Via Pozzuolo 330, 33100 Udine
Want to get in touch with this sponsor?
Send a question and we'll pass it on to MaaT PHARMA.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.